SUBSCRIBE
SUBSCRIBE

GLP-1

BioMidwest
ImageQuantify.com Announces New IQbot For Quantitative Image Analysis Of Eotaxin
September 22, 2016
 · 
2 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Drug Development
Gilead Terminates Phase II/III Study of Ulcerative Colitis Drug
September 21, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Genetown
Boston ‘Unicorn’ Intarcia Banks a Whopping $215 Million to Support Diabetes Drug Pump
September 16, 2016
 · 
3 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Biotech Beach
2 High-Risk Biotechs Ready to Rock—Maybe
August 30, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Merrion Pharma Looks to Wind Up Operations, Announces Liquidation Plans
August 23, 2016
 · 
2 min read
With Hopes of Bolstering Sanofi’s Sagging Diabetes Sector, Announces FDA Approval of Adlyxin in U.S.
FDA
With Hopes of Bolstering Sanofi’s Sagging Diabetes Sector, Announces FDA Approval of Adlyxin in U.S.
July 28, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Novo Nordisk A/S Investors Disappointed as Top Selling Drug Victoza Didn’t Do as Well as Expected
June 14, 2016
 · 
2 min read
Job Trends
Intarcia to Move HQ Next Month, Plans to Double Workforce By End of 2017
June 14, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
As Part of Worldwide Expansion, Novo Nordisk A/S Spends 100 Million Euros to Build in France
April 21, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Eli Lilly Abandons Development of Transition Therapeutics’ Diabetes Candidate TT401
April 18, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways
December 29, 2025
 · 
19 min read
Press Releases
FDA approves Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
December 23, 2025
 · 
14 min read
Press Releases
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
December 23, 2025
 · 
4 min read
Press Releases
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
December 19, 2025
 · 
9 min read
Press Releases
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
December 18, 2025
 · 
24 min read
Press Releases
Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia
December 18, 2025
 · 
4 min read
Press Releases
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
December 18, 2025
 · 
15 min read
Press Releases
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
December 17, 2025
 · 
21 min read
Press Releases
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
December 12, 2025
 · 
5 min read
Press Releases
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
December 11, 2025
 · 
5 min read
Press Releases
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
December 8, 2025
 · 
14 min read
Press Releases
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
December 8, 2025
 · 
12 min read
Press Releases
Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
December 8, 2025
 · 
7 min read
Press Releases
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
December 8, 2025
 · 
1 min read
Press Releases
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
December 2, 2025
 · 
10 min read
Press Releases
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
December 1, 2025
 · 
4 min read
Press Releases
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
November 27, 2025
 · 
3 min read
Press Releases
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096
November 27, 2025
 · 
6 min read
Press Releases
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
November 26, 2025
 · 
6 min read
Press Releases
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
November 25, 2025
 · 
5 min read
Load More